Clinical trials: Central Nervous System Carcinoma
Small Cell Neuroendocrine Carcinoma, Prostate Cancer
Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer
Despite the low androgen receptor (AR) transcriptional activity of treatment-emergent small cell neuroendocrine prostate cancer, there is persistent AR expression observed in the majority of treatment-emergent small-cell…
- Conditions
- Small Cell Neuroendocrine Carcinoma, Prostate Cancer, Small Cell Carcinoma
- Trial name
- NCT04926181
- Testing
- Apalutamide, Cetrelimab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Rahul Aggarwal
Pituitary Tumor
PITUItary Carcinoma or Aggressive Tumors REgistry -Lyon
The purpose of this study is to observe predictors of pituitary tumor recurrence and markers of persistent disease activity through computerized collection of comprehensive demographic, therapeutic, pathologic and outcome…
- Trial name
- PITUICARE-Lyon (NCT02854228)
- Where
- France
- Volunteers
- 1,300 people
- Sponsor
- Hospices Civils de Lyon
Lung Cancer, Lung Cancer Metastatic
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
The purpose of the study is to see if stereotactic radiosurgery/SRS is an effective treatment for people with a new diagnosis of brain metastases from small cell lung cancer/SCLC.
- Conditions
- Lung Cancer, Lung Cancer Metastatic, Brain Metastases, Brain Metastases, Adult
- Trial name
- NCT05419076
- Testing
- Stereotactic Radiosurgery, Cerebrospinal fluid collection
- Where
- 7 sites in United States
- Volunteers
- 62 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma
Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer
This randomized phase II trial studies how well whole-brain radiation therapy or stereotactic radiosurgery with or without lapatinib ditosylate works in treating patients with breast cancer that has too many of a protein called…
- Conditions
- HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma
- Trial name
- NCT01622868
- Testing
- Laboratory Biomarker Analysis, Lapatinib Ditosylate, Stereotactic Radiosurgery
- Where
- 302 sites in United States, Canada and 1 more
- Volunteers
- 143 people
- Sponsor
- National Cancer Institute (NCI)
Periampullary Carcinoma Resectable
The Effect of Braun Anastomosis on Delayed Gastric Emptying (DGE) in Reconstruction After Pancreaticoduodenectomy
Pancreaticoduodenectomy (PD) is the only curative procedure for periampullary malignant tumors. Although modern perioperative management has greatly reduced postoperative mortality, delayed gastric emptying (DGE) remains one of…
- Trial name
- NCT07681128
- Testing
- Braun anastomosis on delayed gastric emptying (DGE) in reconstruction after pancreaticoduodenectomy, Patients undergo PD with standard antecolic Billroth II reconstruction without Braun enteroenterostomy.
- Where
- China
- Volunteers
- 264 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Brain Disease, Metastasis
Gene-expression Profiles in CNS-metastatic Non-small Cell Lung Cancer
Non small-cell lung cancer (NSCLC) accounts 85% of all lung cancer.The development of brain metastasis diminished life expectancy to less than one year with a median survival of less than three months.
- Conditions
- Brain Disease, Metastasis, Lung Cancer
- Trial name
- NCT00862173
- Where
- 2 sites in Mexico
- Volunteers
- 120 people
- Sponsor
- National Institute of Cancerología
Non-small Cell Lung Cancer
Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles
This is a prospective, open-label, single-arm clinical trial. The aim of this study is to evaluate the efficacy and safety of almonertinib and intrathecal chemotherapy in patients with advanced EGFR mutation positive (EGFRm+)…
- Trial name
- NCT05810350
- Testing
- Aumonertinib 165mg orally once daily and intrathecal chemotherapy with pemetrexed
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Three Gorges Hospital of Chongqing University
Nasopharyngeal Carcinoma (NPC)
Brain Alterations Based on Multiplex MR Imaging in Nasopharyngeal Carcinoma Patients After Treatment, and Their Correlation With Clinical Cognitive Scores.
The objective of this study is to examine the potential impact of the treatment before, during, and/or after radiotherapy on the brain in patients with nasopharyngeal carcinoma (NPC) using Multiplex (MTP) MR imaging sequence…
- Trial name
- NPC (NCT07011329)
- Testing
- Changes in the brain MTP parameters after radiotherapy
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hubei Cancer Hospital
Non Small Cell Lung Cancer
Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759
This is a multi-center, open-label, dose escalation and phase I/II study, consisting of dose escalation in Part A and phase II study in Part B.
- Trial name
- NCT03360929
- Testing
- AZD3759
- Where
- 4 sites in China
- Volunteers
- 15 people
- Sponsor
- LYZZ Alpha Holding Ltd
Non Small Cell Lung Cancer, Brain Metastases
A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy
The purpose of this study is to evaluate the efficacy of icotinib alone or in combination with radiation therapy for NSCLC patients harboring EGFR mutation with brain metastases. The primary endpoint is overall survival .
- Trial name
- SMART (NCT04058704)
- Testing
- Icotinib, SRS/WBRT/HA-WBRT/SMART
- Where
- China
- Volunteers
- 296 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants…
- Conditions
- Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
- Trial name
- LIBRETTO-001 (NCT03157128)
- Testing
- LOXO-292
- Where
- 85 sites in United States, Australia and 14 more
- Volunteers
- 857 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumors
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
The purpose of this study is to assess the safety and tolerability of BMS-986484 administered alone, in combination with nivolumab in participants with advanced/metastatic solid tumors including non-small cell lung cancer…
- Trial name
- NCT06544655
- Testing
- BMS-986484, Nivolumab, Oxaliplatin
- Where
- 9 sites in United States, Australia and 1 more
- Volunteers
- 213 people
- Sponsor
- Bristol-Myers Squibb
Lung Cancer, Metastatic Cancer
Stereotactic Radiosurgery and Erlotinib in Treating Patients With Non-Small Cell Lung Cancer and Brain Metastases
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00738335
- Testing
- erlotinib hydrochloride, immunoenzyme technique, laboratory biomarker analysis
- Where
- United States
- Sponsor
- University of California, San Francisco
Lung Cancer, Nonsmall Cell
High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases
The investigators were to explore whether high-dose Furmonertinib, compared with osimertinib, could achieve longer survival in patients with EGFR-mutated NSCLC with CNS metastasis.
- Trial name
- NCT06319950
- Testing
- Furmonertinib, Osimertinib
- Volunteers
- 255 people
- Sponsor
- Taizhou Hospital
Central Nervous System Tumor, Pediatric, Glioma
HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors
This is a Phase 1 study of central nervous system (CNS) locoregional adoptive therapy with autologous CD4 and CD8 T cells lentivirally transduced to express a HER2-specific chimeric antigen receptor (CAR) and EGFRt, delivered by…
- Conditions
- Central Nervous System Tumor, Pediatric, Glioma, Ependymoma, Medulloblastoma
- Trial name
- NCT03500991
- Testing
- HER2-specific chimeric antigen receptor (CAR) T cell
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Seattle Children's Hospital
NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Gene Mutations
Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases
This is a prospective, open-label, multi-center, single-arm clinical trial
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Gene Mutations, Brain Metastasis
- Trial name
- NCT07343479
- Testing
- sac-TMT plus EGFR-TKI
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Zhejiang Cancer Hospital
Leptomeningeal Metastasis, Lung Neoplasms, Non-Small Cell Lung Cancer
Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study
The goal of this clinical trial is to explore the efficacy and safety of double-dose third-generation EGFR-TKI combined with bevacizumab and intrathecal chemotherapy in treating advanced non-small cell lung cancer (NSCLC)…
- Trial name
- NCT07398599
- Testing
- a combined regimen consisting of double-dose third-generation EGFR-TKI, bevacizumab, and intrathecal chemotherapy in patients
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Brain and Central Nervous System Tumors
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
RATIONALE: In this study a combination of anti-cancer drugs (chemotherapy) is used to treat brain tumors in young children. Using chemotherapy gives the brain more time to develop before radiation is given.
- Trial name
- NCT00602667
- Testing
- Induction Chemotherapy, Low-Risk Therapy, High-Risk Therapy
- Where
- 6 sites in United States, Australia
- Volunteers
- 293 people
- Sponsor
- St. Jude Children's Research Hospital
Non-Small Cell Lung Cancer, Brain Metastasis
Efficacy of Gefitinib for Brain Metastasis of Non-Small Cell Lung Cancer
This is a non-randomized open-label uncontrolled phase II trial evaluating efficacy and toxicity of gefitinib in patients with asymptomatic advanced NSCLC who was benefitted by first line chemotherapy.
- Trial name
- NCT00614809
- Testing
- gefitinib
- Volunteers
- 45 people
- Sponsor
- Guangdong Provincial People's Hospital
Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib
Patients with advanced HER2+ breast cancer on maintenance trastuzumab/pertuzumab or T-DM1 with 1st or 2nd intracranial disease event (brain metastases) and stable extracranial disease will be enrolled.
- Conditions
- Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer
- Trial name
- BRIDGET (NCT05323955)
- Testing
- Trastuzumab, Trastuzumab Emtansine (T-DM1), Pertuzumab
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Carey Anders, M.D.